



Docket No.: 66262-00002USPT  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Yash P. Sharma

Serial No.: 09/474,677

Filed: December 29, 1999

For: Treatment and Prevention of HIV and Other  
Viral Infections

§  
§  
§  
§  
§  
§  
§

Group Art Unit.: 1644

Examiner: Ronald B. Schwadron

**INFORMATION DISCLOSURE STATEMENT (IDS)**

**CERTIFICATE OF MAILING 37 CFR 1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Mail Stop Missing Parts, P.O. Box 1450, Alexandria, VA 22313-1450 on March 31, 2005.

*Karen L. Hudson*  
Signature

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

04/05/2005 MBERHE 00000101 100447 09474677  
01 FC:1806 180.00 DA

Dear Sir:

In compliance with the duty of disclosure under 37 C.F.R. §1.56, it is respectfully requested that this be entered and the documents listed on attached Form PTO-SB08 be considered by the Examiner and made of record. Copies of the listed journal articles are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§1.97(g),(h), this Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

A fee as set forth in 37 C.F.R. §1.17(p) in the amount of \$180.00 is due. The Director is hereby authorized to deduct said fee from, Jenkins & Gilchrist, Deposit Account No. 10-0447 (66262-00002USPT), that the listed documents be made of record in the present case.

Serial No.: 09/474,677

Docket No.: 66262-00002USPT

Dated: March 31, 2005

Respectfully submitted,

By 

Robert W. Busby, Jr.

Registration No.: 40,932


JENKENS & GILCHRIST, A PROFESSIONAL  
CORPORATION

901 15th Street, Suite 900

Washington, DC 20005

(202) 326-1500

(202) 326-1555 (Fax)



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	09/474,677
				Filing Date	December 29, 1999
				First Named Inventor	Yash Sharma
				Art Unit	1644
				Examiner Name	Ronald B. Schwadron, PhD
Sheet	1	of	3	Attorney Docket Number	66262-00002USPT

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA**	4,774,327	09-27-1988	Ogura et al.	
	AB**	5,459,031	10-17-1995	Blumen et al.	
	AC**	5,888,514	03-30-1999	Weisman	
	AD**	5,985,330	11-16-1999	Collin	
	AE**	6,143,533	11-07-2000	Sumi et al.	
	AF**	20020013368	01-31-2002	Collin et al.	
	AG**	20020176887	11-28-2002	Lord et al.	
	AH**	20030165480	09-04-2003	Zhu	
		20040039066	02-26-2001	Crea	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
		Muchmore, E.A., Chimpanzee models for human disease and immunobiology. Immunol Rev. 2001; 183:86-93.			
		Taiyeb-Ali, et al., Efficacy of 'Gamadent' toothpaste on the healing of gingival tissues, a preliminary report. J Oral Sci 2003; 45:153-159.			
		Buscher, H.P., et al., Biosynthesis of N-glycolylneuraminic acid in porcine submandibular glands. Subcellular site of hydroxylation of N-acetylneuraminic acid in the course of glycoprotein biosynthesis. Eur J Biochem. 1977; 77(2):297-310.			
		NIAID Anti-HIV Compound Lukor			
		CNN.com, Study: Stem cell lines contaminated, Jan. 23, 2005.			
		Muchmore, et al., Biosynthesis of N-Glycolyneuraminic Acid. J of Biol Chem 1989; 264(34):20216-20223.			
		Shaw and Schauer, The biosynthesis of N-glycolylneuraminic acid occurs by hydroxylation of the CMP-glycoside of N-acetylneuraminic acid. Biol Chem Hoppe Seyler 1988; 369(6):477-486.			
		Sumi, et al., Purification and identification of N-glycolylneuraminic acid (Neu5Gc) from the			
Examiner Signature				Date Considered	

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/474,677
				Filing Date	December 29, 1999
				First Named Inventor	Yash Sharma
				Art Unit	1644
				Examiner Name	Ronald B. Schwadron, PhD
Sheet	2	of	3	Attorney Docket Number	66262-00002USPT

	Holothuroidea gumi, Cucumaria echinata. Prep Bioch and Biotech 2001; 31:135-146.	
	McAuliffe, J., et al., Synthesis of O-glycolyl-linked neuraminic acids through a spirocyclic intermediate. Org Lett. 2002;4(18):3067-3069.	
	Varki and Diaz, The release and purification of sialic acids from glycoconjugates: methods to minimize the loss and migration of O-acetyl groups. Anal Biochem 1984; 137(1):236-247.	
	Schauer and Wember, Hydroxylation and O-acetylation of N-acetylneuraminic acid bound to glycoproteins of isolated subcellular membranes from porcine and bovine submaxillary glands. Hoppe Seylers Z Physiol Chem. 1971; 352(10):1282- 1290.	
	Chou, et al., A mutation in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence. Proc Natl Acad Sci U S A. 1998; 95(20): 11751-11756.	
	Tangvoranuntakul, et al., Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Natl Acad Sci U S A. 2003; 100(21): 12045-12050. published online before print October 1, 2003	
	Suzuki K., The pattern of mammalian brain gangliosides. 3. Regional and developmental differences. J Neurochem. 1965;12(12):969-979.	
	Suzuki K., The pattern of mammalian brain gangliosides. 2. Evaluation of the Extraction Procedures, Post-Mortem Changes and the Effect of Formalin Preservation. J Neurochem. 1965;12:629-638.	
	Ledeen and Yu, Gangliosides: structure, isolation, and analysis. Methods Enzymol. 1982;83:139-191.	
	Klein, et al., New sialic acids from biological sources identified by a comprehensive and sensitive approach: liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS) of SIA quinoxalinones. Glycobiology. 1997;7(3):421-432.	
	Letvin, N.L., Vaccines against human immunodeficiency virus--progress and prospects. N Engl J Med. 1993;329(19):1400-1405.	
	Graham and Wright, Candidate AIDS vaccines. N Engl J Med. 1995;333(20):1331-1339.	
	Etemad-Moghadam, et al., Determinants of neutralization resistance in the envelope glycoproteins of a simian-human immunodeficiency virus passaged in vivo. J Virol. 1999;73(10):8873-8879.	
	Pantaleo and Fauci, Immunopathogenesis of HIV infection. Annu Rev Microbiol. 1996;50:825-854.	
	Etemad-Moghadam, et al., Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeys. J Virol. 1998;72(10):8437-8445.	
	Zolla-Pazner, et al., Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees. J Virol. 1998;72(2):1052-1059.	
	Faillard and Blohm, [Synthesis of N-glycolyneuraminic acid]. Hoppe Seylers Z Physiol Chem. 1965;341(4):167-171. German.	
	Meindl and Tuppy, Monatshefte fuer Chemie, 1969;100:1295-1306.	
	Wirtz-Peitz, et al., [Synthesis of N-acyl-neuraminic acids from neuraminic acid-beta-methylglycoside. I]. Hoppe Seylers Z Physiol Chem. 1969;350(2):111-115. German.	
	Sugata, et al., A Facile Preparation of the Methyl 2-Thioglycoside of N-Glycolyneuraminic Acid, An Efficient Donor of NeuGc. Tetrahedron Lett., 1996;37(15):2613-2614.	
	Simeoni, et al., Synthesis of N -glycolyneuraminic Acid Ethylthioglycoside and Their Use as Glycosyl Donors. Russian Journal Of Bioorganic Chemistry, 1996;22:513 - 519.	
	Chai, et al., Characterisation by mass spectrometry and 1H-NMR of novel hexasaccharides	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/474,677
				Filing Date	December 29, 1999
				First Named Inventor	Yash Sharma
				Art Unit	1644
				Examiner Name	Ronald B. Schwadron, PhD
Sheet	3	of	3	Attorney Docket Number	66262-00002USPT

		among the acidic O-linked carbohydrate chains of bovine submaxillary mucin. Eur J Biochem 1992;207:973-980.	
		Hummel and Schmidt, A versatile Synthesis of the lactoneo-Series antigens -Synthesis of the Sialyl Dimer Lewis X and Dimer Lewis Y. Tetrahedron Letters 1997;38:1173-1176.	
		Dwek, Glycobiology: Toward Understanding the Function of Sugars. Chem Rev. 1996;96(2):683-720.	
		Karkas and Chargaff. Studies on the Stability of Simple Derivatives of Sialic Acid. J Biol Chem. 1964;239:949-957.	
		Stamatos, et al., Desialylation of peripheral blood mononuclear cells promotes growth of HIV-1. Virology 1997;228(2):123-31.	
		Lepers, et al., A study on the regulation of N-glycolylneuraminic acid biosynthesis and utilization in rat and mouse liver. Eur J Biochem. 1990;193(3):715-23.	
		Varki A. N-glycolylneuraminic acid deficiency in humans. Biochimie. 2001;83(7): 615-622.	
		Normile D. Comparative genomics. Gene expression differs in human and chimp brains.Science. 2001 Apr 6;292(5514):44-45.	
		Moreno E, et al. Delineation of the epitope recognized by an antibody specific for N-glycolylneuraminic acid-containing gangliosides. Glycobiology. 1998 Jul;8(7):695-705.	
		Varki A. Loss of N-glycolylneuraminic acid in humans: Mechanisms, consequences, and implications for hominid evolution. American Journal of Physical Anthropology. 2002;116(S33):54-69.	
		Bardor, et al. Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells. J. Biol. Chem. 2005 Feb;280(6):4228-4237	
		Tram, et al. Sialic acid content of infant saliva: comparison of breast fed with formula fed infants. Arch. Dis. Child. 1997;77:315-318.	
		Muchmore, et al. A structural difference between the cell surfaces of humans and great apes. Am. J. Phys. Anthropol. 1998 Oct;107(2):187-198.	
		Beaumont, et al. Increased Neutralization Sensitivity and Reduced Replicative capacity of Human Immunodeficiency Virus Type 1 after Short-Term In Vivo or In Vitro Passage through Chimpanzees. Journal of Virology 2000;74(17):7699-7707.	
		<a href="http://www.herbshop.com/np_spec1.htm">www.herbshop.com/np_spec1.htm</a> Connect-All	
		<a href="http://www.lifeplusvitamins.com/skin-care-beauty.htm">www.lifeplusvitamins.com/skin-care-beauty.htm</a> Forever Young Tablets	
		<a href="http://www.greenbarley.com/mercare.html">www.greenbarley.com/mercare.html</a> Mer Care	
		<a href="http://www.zooscape.com/cgi-bin/maitred/GreenCanyon/Questp405475">www.zooscape.com/cgi-bin/maitred/GreenCanyon/Questp405475</a> Joint Support	
		<a href="http://www.pnas.org/cgi/content/full/2131556100/DC1/7">www.pnas.org/cgi/content/full/2131556100/DC1/7</a> Table 2. Sia and Neu5Gc content of common food items	
		<a href="http://www.seacucumber.cn/english/theory.asp">www.seacucumber.cn/english/theory.asp</a>	
		<a href="http://www.itmonline.org/arts/seacuke.htm">www.itmonline.org/arts/seacuke.htm</a>	
		<a href="http://www.scienceblog.com/community/article1994.html">www.scienceblog.com/community/article1994.html</a>	
		<a href="http://www.hon.ch/News/HSN/515312.html">www.hon.ch/News/HSN/515312.html</a>	
		<a href="http://www.health.ucsd.edu/news/2003/09_29_Varki.html">www.health.ucsd.edu/news/2003/09_29_Varki.html</a>	
		<a href="http://www.msnbc.com/news/973366.asp?cp1=1">www.msnbc.com/news/973366.asp?cp1=1</a>	
		<a href="http://www.easycart.net/cgi-bin/BeyondACenturyInc./search.cgi">www.easycart.net/cgi-bin/BeyondACenturyInc./search.cgi</a>	
		<a href="http://www.casbellarmine.edu/tietjen/RootWeb/which_of_our_genes_make_us_human.htm">www.casbellarmine.edu/tietjen/RootWeb/which_of_our_genes_make_us_human.htm</a>	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--